Hennion & Walsh Asset Management, Inc. Adc Therapeutics Sa Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 17, 2024	BUY	$1.66 - $5.29 $7,802 - $24,863	4,700 Added 7.13%	70,636 $317,000
Q4 2023 Jan 10, 2024	BUY	$0.47 - $1.79 $3,792 - $14,443	8,069 Added 13.94%	65,936 $109,000
Q3 2023 Oct 27, 2023	BUY	$0.72 - $2.37 $1,654 - $5,446	2,298 Added 4.14%	57,867 $52,000
Q2 2023 Aug 09, 2023	SELL	$1.9 - $2.66 $2,844 - $3,982	-1,497 Reduced 2.62%	55,569 $119,000
Q1 2023 Apr 20, 2023	SELL	$1.92 - $5.45 $3,461 - $9,826	-1,803 Reduced 3.06%	57,066 $111,000
Q4 2022 Jan 12, 2023	BUY	$2.87 - $5.24 $21,057 - $38,445	7,337 Added 14.24%	58,869 $226,000
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $59,797 - $132,297	12,832 Added 33.16%	51,532 $248,000
Q2 2022 Jul 19, 2022	BUY	$5.96 - $14.99 $230,652 - $580,113	38,700 New	38,700 $308,000

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $172M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.